IsoPlexis will use four new NIH grants to advance research and development of immunotherapies to treat solid tumors, bone marrow disease, autoimmune diseases and infectious diseases.

Branford, Conn.—IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, announced today that it has received four new grants from the National Institutes of Health (NIH), with a total of $5.6 million in new funding, to advance different areas of precision medicine.

Using this NIH funding, IsoPlexis will develop a variety of products and technologies, including single-cell assay panels, automated platforms and bioinformatics tools targeted towards various immunology and oncology applications. These systems aim to allow clinical researchers at leading academic centers and biopharmaceutical companies to better target complex tumor infiltrating lymphocytes-focused immunotherapies for solid tumors, diagnose stages of bone marrow disease and autoimmune diseases, and develop infectious disease vaccines.

These new single-cell platforms and tools will build on inventions core to the company, such as the IsoCode Chip, to detect cellular responses at the single-cell level. The IsoCode Chip is already helping researchers better understand how to develop potent personalized immune therapies for various blood cancers.

“We’re excited to use this NIH grant support to advance our research and development in areas of solid tumor immunotherapies, bone marrow disease, autoimmune diseases and infectious diseases,” said Sean Mackay, IsoPlexis CEO and Co-Founder. “By expanding the application of our single-cell detection technologies, we aim to enable clinical researchers to better target their personalized treatments, at the single-cell level, and improve outcomes for high-need patients.”

NIH Grant Highlights

Automated Single-Cell System to Analyze Rare T-Cells (TILs) From Solid Tumors. IsoPlexis is using this $1.94 million grant to develop an advanced assay panel and automated fluidics platform capable of capturing 32 different functional proteins per T-cell to characterize the functional sensitivity of therapeutic tumor infiltrating lymphocytes (TILs) from patients undergoing checkpoint therapeutics. The goal of this project is to enable clinical researchers to evaluate patient TIL response with high sensitivity to differentiate and effectively stratify responding and non-responding patients.

Single-Cell Chip and Software Enabling Detection and Diagnoses of Pathogenic Cell Populations in Bone Marrow Diseases Within Oncology. IsoPlexis is using this $1.71 million grant to develop a fluidic chip and software system designed to recognize and capture at least 22 different secreted proteins per inflammatory cancer cell to characterize and compare bone marrow cell samples from patients with bone marrow disease. The goal of the project is to eventually allow clinical researchers and clinicians to apply the technology directly to the detection of pathogenic populations of cells in myelofibrosis and to be able to differentiate stages of disease for future targeted treatment.

ABOUT ISOPLEXIS:

IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single-cell level, IsoPlexis’ original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures, and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit https://www.isoplexis.com or email info@isoplexis.com.